•  
  •  
 

Subject Area

Hematology

Article Type

Original Study

Abstract

Objectives: To analyze the serum level of lysosomal-associated protein transmembrane-4 beta (LAPTM4B) in newly diagnosed patients with diffuse large Bcell lymphoma (DLBCL) and to study its association with established prognostic factors in DLBCL. Background: DLBCL is a cancer with a considerable variability in patients’ outcomes and prognosis, resulting in the crucial need to identify new prognostic biomarkers. Even after approval of new therapeutic options, treatment of refractory and relapsed lymphomas remains a challenging obstacle. Increasing evidence of involvement of LAPTM4B in carcinogenesis has been recently reported. Furthermore, LAPTM4B was suggested as a potential candidate for targeted therapy. Methods: A total of 30 patients who were newly diagnosed with DLBCL were investigated for clinical characteristics, basic laboratory workup and serum LAPTM4B. Additionally, 30 apparently heathy individuals were included as the control group. Results: Data analysis revealed that LAPTM4B was detected at high levels in the serum of DLBCL patients as compared to control group (P=0.005). High levels of serum LAPTM4B were significantly linked to advanced disease stage, involvement of > extranodal site, international prognostic index with ≥3, decreased hemoglobin levels, and increased blood lymphocytes percentages (P=0.039, P=0.008, P=0.010, P=0.015, P=0.021; respectively). Moreover, we reported that high serum LAPTM4B at diagnosis was significantly associated with failure to achieve complete remission (P=0.035). Conclusion: Seum LAPTM4B may be used as a promising biomarker for assessment of prognosis and therapy response of DLBCL patients.

Download

Share

COinS